Association analysis ofCYP2A6genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes

High prevalence of CYP2A6⁎4 and CYP2A6⁎9 alleles detected among a Malaysian population

(2009) Wardah Yusof et al.   CLINICA CHIMICA ACTA

Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6

(2009) Yuan Di et al.   CURRENT DRUG METABOLISM

Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors

(2009) Nael Al Koudsi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Association ofCYP2A6polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer

(2009) Sun-Young Kong et al.   PHARMACOGENOMICS

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

(2008) Ulrich M. Zanger et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1

(2008) Ken-ichi Fujita et al.   CANCER SCIENCE

The CYP2A6*4 Allele Is Determinant of S-1 Pharmacokinetics in Japanese Patients With Non-small-cell Lung Cancer

(2008) Y Kaida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent

(2008) Jill C. Mwenifumbo et al.   HUMAN MUTATION

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY

Genetic polymorphism analysis ofCYP2C19in Chinese Han populations from different geographic areas of mainland China

(2008) Lingling Chen et al.   PHARMACOGENOMICS